Beyond Basics: Project Limetree session 1

In CSF testing, the presence of ______ in the brain is determined by Aβ42/40 and Aβ42.

• Amyloid accumulation

• Tau tangles

• Neuroinflammation

• Synaptic dysfunction

In plasma, ______ is being recognized as having the same clinical significance as CSF markers & PET in the USA, with a similar trend seen in Japan.

• Neurofilament light chain (NfL)

• Aβ 1-40

• pTau217

• pTau181

LEQEMBI (Lecanemab) targets protofibrils, while KISUNLA (Donanemab) is the first and only ______ targeting therapy

• Astrocyte

• Tau fibrils

• Synaptic proteins

• Amyloid plaque

Testing for ______ status should be performed before starting treatment to assess the risk of developing ARIA.

• Total Tau

• ApoE ε4

• Aβ 1-42

• NfL

Excellent clinical concordance has been observed between Lumipulse G and ______ (Neuro standard kit by Fujirebio Europe).

• INNOTEST
• Roche Elecsys

• Lilly MSD

• ALZpath Simoa

These FDA-approved CSF tests provide benchmarks for the performance of AD biomarker tests, suggesting a ______ % sensitivity and specificity for _______.

• 90% and FDG-PET

• 70% and amyloid PET

• 90% and amyloid PET

• 90% and MRI Brain

Plasma ______ & ______/Aβ1-42 ratio indicate Aβ accumulation in the brain with high accuracy compared to other biomarkers.

• pTau217 & pTau217

• Aβ 1-42 & Aβ 1-40

• pTau217 & Aβ 1-40

• pTau181 & pTau217

The only international standard material for ______ in CSF is available

• Aβ 1-42

• Aβ 1-40

• Total Tau

• NfL

After centrifugation of blood-contaminated CSF samples, if no hemolysis is observed, it is recommended to test the supernatant or ______ the blood-contaminated sample.

• Filter and proceed

• Store at -80°C for 24 hours

• Heat-treat

• Not to use